GLP-1 kwayoyi kamar Ozempic da Wegovy
- Sabon binciken da aka gabatar a Cibiyar Nazarin Kimiyya ta Ƙungiyar Zuciya ta Amirka ya nuna cewa semaglutide, mai aiki a cikin Ozempic da Wegovy, yana da tasiri mai mahimmanci akan lafiyar zuciya.
- Shaidu sun nuna cewa marasa lafiya da aka yi wa maganin GLP-1 sun rage haɗarin bugun zuciya da bugun jini.
- Alamun gazawar zuciya kuma sun inganta yayin jiyya tare da semaglutide.
Semaglutide, maganin GLP-1 da aka fara wajabta don ciwon sukari sannan kuma kiba, zai iya magance cututtukan zuciya da jijiyoyin jini.
A karshen mako, a Cibiyar Nazarin Kimiyyar Zuciya ta Amurka 2023, masu bincike sun gabatar da kwararan hujjoji na tasirin semaglutide (wanda aka sayar a ƙarƙashin alamun Wegovy da Ozempic) don hana bugun zuciya da bugun jini.
Wani bincike kuma ya nuna cewa za a iya amfani da miyagun ƙwayoyi don inganta bayyanar cututtuka a cikin marasa lafiya da ciwon zuciya, musamman rashin ciwon zuciya tare da ɓangarorin cirewa (HFpEF).
A hade, binciken biyu, wanda aka buga daga baya a cikin manyan mujallu na likita, sun nuna alƙawarin don semaglutide a matsayin zaɓi na magani ga marasa lafiya da ke cikin haɗarin manyan cututtukan zuciya da cututtukan zuciya.
A cikin duka biyun, Novo Nordisk, wanda ya yi Ozempic da Wegovy ne ya dauki nauyin binciken.
Shin semaglutide yana da fa'idar bugun jini?
Wani binciken da aka gabatar a wannan karshen mako kuma an buga shi lokaci guda a cikin New England Journal of Medicine yayi nazarin sakamakon daga gwajin SELECT, mai yawa, makafi biyu, bazuwar, gwajin gwajin wuribo wanda Novo Nordisk ya gudanar don nazarin sakamakon cututtukan zuciya a cikin marasa lafiya da aka bi da su tare da semaglutide. da placebo.
Binciken da aka gabatar a karshen mako ya yi nazari kan adadin mace-macen da ake samu, da ciwon zuciya da ba sa mutuwa, da kuma bugun jini a cikin marasa lafiya da ba su da ciwon sukari. An nuna magungunan a baya don rage waɗannan abubuwan da ke faruwa a cikin marasa lafiya da nau'in ciwon sukari na 2.
Gwajin dai ita ce mafi girma da kamfanin harhada magunguna na kasar Denmark ya taba gudanarwa kuma ya hada da mahalarta sama da 17 a kasashe 000.
An gudanar da binciken tsakanin Oktoba 2018 da Maris 2021 kuma ya dade shekaru biyar, ciki har da lokacin bin haƙuri.
A lokacin gwajin, rabin mahalarta sun sami semaglutide (kashi na 2,4 MG sau ɗaya a mako), yayin da sauran rabin sun sami placebo. Marasa lafiya a cikin gwajin sun kasance shekaru 45 ko tsufa, suna da BMI na 27 ko mafi girma, kuma suna da cututtukan zuciya da suka rigaya. Dole ne ba su da tarihin ciwon sukari.
Marasa lafiya waɗanda suka ɗauki semaglutide sun sami raguwar haɗarin matsalolin cututtukan zuciya da yawa a cikin jirgi: haɗarin haɗarin cututtukan zuciya ya ragu da 20%, haɗarin bugun zuciya da 28%, da haɗarin bugun jini ta 7%.
Akwai ƙarin fa'idodi kuma. Ƙungiyar semaglutide ta rasa 9,39% na nauyin jikinsu, idan aka kwatanta da kasa da 1% na rukunin placebo. Sun kuma ga inganta hawan jini, matakan cholesterol da matakan HbA1c.
Novo Nordisk a baya ya fitar da bayanan asali akan sakamakon gwaji na SELECT a watan Agusta.
Shin semaglutide yana taimakawa tare da gazawar zuciya?
Binciken da aka buga a ranar Nuwamba 12 a CirculationBuga flagship na Ƙungiyar Zuciya ta Amurka, ta yi nazarin maganin semaglutide don inganta alamun gazawar zuciya tare da ɓangarorin da aka adana, mafi yawan nau'in ciwon zuciya.
Masu bincike sun kalli matakan daban-daban a wurare kamar ingancin rayuwa, ƙayyadaddun zamantakewa, da ƙayyadaddun jiki ta amfani da Kansas City Cardiomyopathy Questionnaire (KCCQ), wanda ke ba da maki ga alamun rashin ciwon zuciya bisa jerin dalilai.
Makonni 52, bazuwar, makafi biyu, gwajin sarrafa wuribo ya haɗa da mahalarta 529. Rabin mahalarta sun sami allurar mako-mako na 2,4 MG na semaglutide, yayin da sauran rabin sun sami placebo. Dole ne marasa lafiya su sami kiba da kuma tarihin da aka rubuta na HFpEF.
Mutanen da aka bi da su tare da semaglutide sun sami ci gaba mai mahimmanci a cikin alamun gazawar zuciya, wanda aka nuna ta hanyar haɓakawa a cikin ƙimar KCCQ, raguwa mafi girma a cikin nauyin jiki, da haɓakawa a cikin iyakokin jiki da aikin motsa jiki.
"Yanzu muna kan wannan bala'in bayanan da ke nuna mana da gaske kan cewa kiba ce ke haifar da wadannan rikice-rikice. Domin gudanar da waɗannan matsalolin yadda ya kamata, muna buƙatar magance kiba, muna buƙatar ƙaddamar da kiba, "Dokta Mikhail Kosiborod, likitan zuciya, mataimakin shugaban bincike a Tsarin Kiwon Lafiya na Saint Luke da jagoran marubucin binciken. binciken, in ji Healthline.
Sakamakon ya dogara ne akan binciken da aka buga a baya a farkon wannan shekara.
HFpEF yana nufin nau'in raunin zuciya iri-iri wanda zuciyar ta yi taurin kai don cikawa da kyau.
Kodayake gazawar zuciya da kiba yanayi ne na kiwon lafiya daban, galibi suna faruwa tare. A review in Jama A farkon wannan shekarar, an gano cewa mutanen da ke da kiba ko kiba BMI suna da haɗarin HFpEF da yawa.
Dokta Lynne Warner Stevenson, farfesa na likitancin zuciya a Vanderbilt da kuma darektan shirin su na cardiomyopathy, wanda ba shi da alaƙa da binciken, ya gaya wa Healthline:
“Karshen wannan guguwar ce ta bullo da ita don neman hanyar da za a bi don rage cututtuka da mace-macen abin da na dauka a matsayin hoton Venn na cututtuka, wato kiba da ciwon suga da cututtukan zuciya. gazawar da aka adana juzu'in fitarwa.
Magungunan GLP-1 suna taimakawa wajen magance ciwon sukari, kiba da cututtukan zuciya
"Ina tsammanin kowa yana jin dadi kuma duk mun jira, musamman gwajin SELECT, kuma ina ganin labari ne mai kyau," in ji Dokta Sun Kim, mataimakin farfesa a fannin likitanci a cikin ilimin endocrinology a Jami'ar Stanford, ya shaida wa Healthline. Ba ta shiga cikin binciken ba.
"Masu ilimin endocrinologists suna da alaƙa ta musamman ga wannan rukunin magungunan saboda an fara yarda da su don maganin ciwon sukari na 2 da kuma kula da sukarin jini, amma an nuna cewa suna da ƙarin fa'idodi da yawa," in ji ta.
Marubutan edita mai rakiya a cikin NEJM ya rubuta: "Muna cikin sabon zamani na magance kiba da haɗarin cardiometabolic tare da haɓakar arsenal na zaɓuɓɓuka. Gwajin SELECT yana ba da shaida na ingantattun sakamakon cututtukan zuciya tare da GLP-1 agonists masu karɓa a cikin rashin ciwon sukari.
Koyaya, sun kuma lura cewa farashi da samun damar yin amfani da semaglutide ya kasance babban cikas ga mutane da yawa.
Novo Nordisk ya shigar da aikace-aikace don sabunta alamar Wegovy don haɗawa da nuni don rage manyan abubuwan da suka faru na zuciya da jijiyoyin jini. FDA ta ba da fifikon sabuntawa don wannan ƙarin sabon aikace-aikacen magani.
Kamfanin ya ba da Healthline tare da bayanin mai zuwa daga Dr. Michelle Skinner, PharmD, jagoran yanki na likitancin zuciya, al'amuran kiwon lafiya a Novo Nordisk:
“Cikakken sakamakon SELECT da aka gabatar a AHA alama ce ta juyi a kimiyyar kiba. Muna sa ran yin aiki tare da masu gudanarwa kan matakai na gaba don samar da wannan zaɓi ga mutanen da ke da kiba ko kiba da kuma ma'aikatan kiwon lafiya waɗanda ke haɗin gwiwa a cikin kulawarsu.
Mai
Shaidu masu tasowa sun nuna cewa semaglutide na iya samun fa'idodi masu mahimmanci akan lafiyar zuciya da gazawar zuciya.
Dangane da bayanai daga gwaji na Novo Nordisk's SELECT, marasa lafiya da aka yi musu magani tare da semaglutide sun rage kashi 20% gabaɗayan haɗarin mummunan cututtukan zuciya da jijiyoyin jini idan aka kwatanta da placebo.
Wani gwaji na daban kuma ya nuna maganin yana da tasiri wajen magance alamun gazawar zuciya tare da tsayayyen juzu'in fitarwa.
KARA KARANTAWA KA KARA KARANTAWA KA ARA KARA KARANTAWA KA ARA KARA KARANTAWA